<![CDATA[UCSF Receives Major Gift to Advance Research and Modernization]]>

Press Release|Articles|May 13, 2026 UCSF Receives Major Gift to Advance Research and Modernization Author(s)UCSF Health Listen0:00 / 0:00 Key Takeaways A $100M commitment provides flexible funding across UCSF capital expansion, priority-driven innovation, and the Weill Cancer Hub West to accelerate cancer discovery and treatment. Modernization plans target Parnassus Heights redevelopment and UCSF Health Helen Diller Hospital construction, alongside UCSF Benioff Children’s Hospital Oakland upgrades with 104 new inpatient beds. A dedicated 20-bed inpatient behavioral health unit at the Oakland site addresses a critical pediatric capacity gap within broader hospital modernization. IMPACC, supported by prior philanthropy, will evaluate real-world safety, efficacy, and equity impacts of deployed clinical AI, including detection of unintended disparity amplification. Cross-campus translational initiatives link human and veterinary medicine, including UC Davis infrastructure expansion and comparative oncology trials (e.g., feline squamous cell carcinoma) with potential human relevance.SHOW MORE Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine. UC San Francisco has received a $100 million commitment from longtime supporters Kathy Chiao and Kenneth (Ken) Hao to address its most urgent capital needs and accelerate innovation to advance human health.The investment will enable UCSF to seize emerging opportunities across its mission, with $50 million supporting capital projects, $40 million advancing innovation initiatives aligned with evolving priorities, and $10 million dedicated to the Weill Cancer Hub West, a UCSF-Stanford collaboration that is driving new discoveries in cancer research and treatment.“Ken and Kathy have been extraordinary partners to UCSF for many years, and this remarkable gift comes at a pivotal moment,” said UCSF Chancellor Sam Hawgood, MBBS. “Their generosity gives us the flexibility to expand our hospitals and accelerate the most promising and innovative work when it matters most.”The university’s capital priorities include modernization of the century-old Parnassus Heights campus, featuring a new, state-of-the-art UCSF Health Helen Diller Hospital, as well as a new hospital building as part of the modernization of UCSF Benioff Children’s Hospital Oakland. The Oakland project will add 104 inpatient beds, including a much-needed 20-bed inpatient behavioral health unit.“UCSF and the University of California represent one of the most powerful engines for innovation and public impact in the world,” Hao said. “Kathy and I are big believers in the magic produced by the very best academic medical centers and are proud to support the amazing people at UCSF.”Longtime UC engagement spurs new supportChiao and Hao are longtime supporters of academic hospitals and the health sciences. With decades of advisory service to UCSF, Hao currently serves as vice chair of the UCSF Board of Directors and as co-chair of the UCSF Health Executive Council. Hao’s investment acumen, particularly in the technology field, has been significant for UCSF as it navigates the rapidly changing landscape of science, health care, and higher education.The UCSF donation comes on the heels of a $75 million contribution by the couple to the UC Davis Weill School of Veterinary Medicine. The UC Davis gift, announced April 23, will support the construction of a new small-animal hospital, which will be among the most advanced veterinary medical centers in the world. The project will expand UC Davis veterinary care facilities by 50% to serve 75,000 animals each year. The gift will also fund veterinary student scholarships, research projects that connect animal medicine to its human counterparts at UC Davis Health, UCSF, and other institutions, and programs for those unable to afford veterinary care.Chiao and Hao also have supported UC Berkeley School of Public Health through scholarships and the foundational funding for Berkeley’s Impact Innovators, a program that sponsors student leaders to advance community health while building skills in social entrepreneurship and community partnership.Support for AI monitoring, translational researchThe couple has provided substantial funding to UCSF for over a decade, including $5 million last year to develop a real-time AI monitoring platform for clinical care. The project, known as the Impact Monitoring Platform for AI in Clinical Care (IMPACC), aims to assess the safety and efficacy of AI technologies as they are adopted in the clinic.IMPACC will help health care leaders determine whether a tool is achieving its intended results, requires improvement, or poses risks such as worsening health disparities.The couple’s support also will accelerate collaborative work in the field of translational medicine. Their UC Davis gift fuels the potential for new discoveries for animals and humans, as clinicians and researchers from UC Davis, UCSF and other organizations collaborate to find the most effective treatments and research to advance health for all. Among other recent collaborations, UCSF and UC Davis partnered to develop a clinical trial that benefited cats with squamous cell carcinoma, opening potential new paths for treatment in humans.Hao is chairman and a managing partner of Silver Lake, a global technology investment firm. The Chiao-Hao family are residents of the Bay Area. Their philanthropy focuses on medicine and life sciences, education and scholarships, nature and animal welfare, Asian American initiatives, and arts accessibility. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Related ContentAUA and SUO Amend Advanced Prostate Cancer GuidelineByKyle Doherty May 12th 2026Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence RiskByFox Chase Cancer CenterMay 12th 2026FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic CarcinomaByAshling Wahner May 12th 2026[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ByKyle Doherty May 12th 2026FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ByChris RyanMay 12th 2026 Latest CMEMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventIowa Oncology Society1 Session is Available!View moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVirtual EventLouisiana Oncology Society1 Session is Available!View moreVirtual EventMissouri Oncology Society1 Session is Available!View moreVirtual EventNew Mexico Society of Clinical Oncology1 Session is Available!View moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Trending on OncLive1GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 20262FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma3FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma 4[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC 5AUA and SUO Amend Advanced Prostate Cancer Guideline